Representation audits

Were Women Studied?

Enrollment is not analysis. We audit who was included, how outcomes were analyzed by sex, and what evidence gaps remain. Every audit uses the same two-grade schema — representation (R1–R4) and sex-analysis (S1–S5), reported separately.

R1S3

SURMOUNT-1 (NCT04184622) and the broader SURMOUNT program

Women were enrolled in large numbers in the tirzepatide obesity development program, but interpretable sex-specific analyses and life-stage denominators remain limited.

Women / female67.5%

of 2,539 enrolled

Read the audit

R1S2

STEP-1 (NCT03548935)

Women were well represented in the semaglutide weight-management trials, but prespecified sex analyses had limited precision.

Women / female63.2%

of 1,961 enrolled

Read the audit

R3S5

Early-phase kisspeptin studies in PCOS and hypothalamic amenorrhea (multiple small trials)

Kisspeptin studies in women are small and early-phase; no reliable sex-comparative analysis exists.

Women / female0%

of 0 enrolled

Read the audit

R1S4

Leuprolide endometriosis clinical development program

Leuprolide endometriosis trials enrolled women with the condition, but comparative sex analyses are not relevant by design.

Women / female0%

of 0 enrolled

Read the audit

R1S4

Fracture Prevention Trial (NCT00670501) and related osteoporosis trials

Teriparatide osteoporosis trials included large numbers of postmenopausal women; sex-comparative analysis is not applicable to these women-only cohorts.

Women / female100%

of 1,637 enrolled

Read the audit

R1S4

Labor induction and augmentation trials with oxytocin

Oxytocin labor trials enrolled pregnant people; sex analyses are not applicable.

Women / female0%

of 0 enrolled

Read the audit